Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
149.64
-5.16 (-3.33%)
Nov 7, 2025, 1:40 PM EST - Market open
Neurocrine Biosciences Revenue
Neurocrine Biosciences had revenue of $794.90M in the quarter ending September 30, 2025, with 27.78% growth. This brings the company's revenue in the last twelve months to $2.68B, up 19.61% year-over-year. In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B with 24.81% growth.
Revenue (ttm)
$2.68B
Revenue Growth
+19.61%
P/S Ratio
5.74
Revenue / Employee
$1,490,389
Employees
1,800
Market Cap
14.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
| Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
| Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
| Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
| Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NBIX News
- 4 days ago - Biotech is back. Here's why these rallying stocks belong in your portfolio now. - Market Watch
- 9 days ago - Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Neurocrine Biosciences Reports Third Quarter 2025 Financial Results - PRNewsWire
- 20 days ago - Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches - Seeking Alpha
- 21 days ago - Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise - PRNewsWire
- 4 weeks ago - Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea - PRNewsWire